IRIS will increase the share of direct contracts and private label products
By the end of 2019, IRIS expects revenue growth 10% higher than the dynamics of the pharmacy market. The most important direction for gross profit increase is private label developing and promotion. This allows for an increase in the product categories income and attract customers through new offers at the best price.
According to Galina Orlova, in 2019, IRIS plans to increase the share of private label and unconditional private label products twice.
The share of direct contracts will grow, reaching its maximum performance in the regions of presence. This approach is associated with the partnership of its distributors.
Direct contracts give the partnership a stable supply and terms. At the same time, marketing contracts are not a source of IRIS revenue, but exclusively focused on partners.
Take into account that each of the participants take a leading position in the regions, the best practices exchange and mutual study of the matrices allow to create the ideal assortment matrix for a specific region and a specific location.
